Alnylam Pharmaceuticals, Inc.
ALNY
$473.29
$8.361.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 43.57M | -319.09M | -269.70M | -278.16M | -332.26M |
| Total Depreciation and Amortization | 21.61M | 21.79M | 22.84M | 21.96M | 23.50M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 646.53M | 481.93M | 490.34M | 427.89M | 417.82M |
| Change in Net Operating Assets | -445.84M | -200.16M | -288.59M | -180.00M | -52.50M |
| Cash from Operations | 265.86M | -15.54M | -45.11M | -8.31M | 56.56M |
| Capital Expenditure | -44.50M | -36.55M | -30.27M | -34.28M | -40.49M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 465.08M | -74.22M | 94.82M | -82.56M | -264.09M |
| Cash from Investing | 420.59M | -110.77M | 64.55M | -116.84M | -304.59M |
| Total Debt Issued | 646.37M | -- | -- | -- | -- |
| Total Debt Repaid | -1.14B | -- | -- | -- | -- |
| Issuance of Common Stock | 244.61M | 274.90M | 326.46M | 302.95M | 297.57M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -70.10M | -43.31M | -17.13M | -8.79M | 4.82M |
| Cash from Financing | -319.51M | 231.59M | 309.33M | 294.16M | 302.39M |
| Foreign Exchange rate Adjustments | 23.37M | 39.39M | 8.76M | -15.24M | 12.93M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 390.30M | 144.67M | 337.53M | 153.77M | 67.29M |